

### Scleroderma-associated ILD: Clinical manifestations and diagnosis

Robert Hallowell, MD

## Disclosures

- Speaking and consulting fees: Boehringer Ingelheim, Genentech
- Research trials: Boehringer, Genentech, Galapagos, Hoffmann-La Roche, Nitto Denko, Vicore
- Authorship fees: UpToDate, Dynamed





## Scleroderma or Systemic Sclerosis (SSc)

Autoimmune disease characterized by systemic inflammatory, fibrotic, and vasculopathic changes

Divided into three primary subsets:

Limited cutaneous (Skin changes are distal to the elbows and knees; face and neck involvement)
 CREST (<u>C</u>alcinosis, <u>R</u>aynaud's, <u>E</u>sophageal dysmotility, <u>S</u>clerodactyly, <u>T</u>elangiectasias)
 Diffuse cutaneous (Skin changes extend to or beyond the elbows and knees)
 Systemic sclerosis sine scleroderma (No skin thickening; internal involvement and positive antibodies)

We see significant pulmonary involvement with all three subsets of SSc!





# **Rheumatologist Does my SSc patient have ILD?**

### Pulmonologist Does my ILD patient have SSc?











### Symptom review








1. Hush Naidoo Jade images

2. Perelas et al. Lancet Respir Med 2020;8: 304–20

### ILD is common in SSc


- Seen on CT in up to 80% patients
- Seen on autopsy in up to 90% of patients
- Clinically significant in 30-40% of patients
- 10-year mortality of SSc-ILD up to 40%





## ILD is associated with death in SSc

- 162 patients with SSc-ILD
- 12-month PFT trends on 15-year survival
- HR 1.84, p = 0.01



- 5860 SSc patients in the EULAR trials and EUSTAR cohort
- Cause of death analyzed for 234/284 cases
- 33% of deaths attributed to a pulmonary cause; 19% pulmonary fibrosis

 Table 1
 Primary causes of death in 234 patients with SSc

	Ν	%
All death cases	234	100
SSc-related death cases	128	55
Pulmonary	78	33
Pulmonary fibrosis	45	19
Isolated PAH	33	14
Myocardial	33	14
Arrhythmia	14	6
Left heart failure	8	3
Right heart failure	5	2
Biventricular heart failure	4	2
Pericarditis (constriction and/or tamponade)	2	1
Renal	10	4
Renal crisis	10	4
Gastrointestinal	7	3



## **Diagnosing Scleroderma--ACR/EULAR Criteria**

Items	Sub-items	Score
Bilateral skin thickening of the fingers		9
	Puffy fingers	2
	Sclerodactyly	4
Fingertip lesions	Digital tip ulcers	2
	Fingertip pitting scars	3
Telangiectasias		2
Abnormal nailfold capillaries		2
PAH (RHC) or ILD		1-2
Scleroderma related Antibodies	Anti-Centromere Anti-Topoisomerase 1 Anti-polymerase III	1-3

9 points = definite SSc

Sensitivity 91% Specificity 92%



## Autoantibodies in SSc

	Antibody	Frequency in SSc	Disease Subtype	Clinical Association
*	Anti-Topoisomerase 1 (Scl-70)	15% - 42%	dc-SSc	ILD
*	Anti-Centromere	20% - 38%	lc-SSc	РАН
	Anti-Th/To	1% - 13%	lc-SSc	ILD
*	Anti-RNA-polymerase III	5% - 31%	dc-SSc	Renal crisis, synovitis, myositis, tendon friction rubs, malignancy
	Anti-U3-RNP	4%-10%	dc-SSc	Renal crisis, cardiac involvment
	Anti-U1-RNP	2%-14%	lc-SSc	Raynaud's, puffy fingers, arthritis, myositis, MCTD
	Anti-PM-Scl	4%-11%	lc-SSc	ILD, myositis, sicca, calcinosis, arthritis
	Anti-Ku	2%-4%		Myositis, arthritis, joint contractures



### Panel 1: Factors associated with the presence of systemic sclerosis-associated interstitial lung disease

#### Epidemiology

- African American race
- Male sex
- Genetic polymorphisms

#### **Clinical features**

- Diffuse cutaneous scleroderma variant
- Nailfold capillary abnormalities
- Digital ulcers
- Longer disease duration
- Pulmonary hypertension


#### Autoantibodies

- Anti-topoisomerase I
- Anti-neutrophil cytoplasmic antibody
- Anticardiolipin
- Anti-Ro52
- Anti-NOR90
- Anti-U11/U12
- Anti-Th/To
- Anti-polymyositis-scleroderma

#### Novel Biomarkers

- Interleukin-6, interleukin-34
- chemokine (C-X-C motif) ligand 4
- chemokine (C-C motif) ligand 18
- Carbohydrate antigen 15.3
- Lysyl oxidase
- Tenascin-C
- Serum amyloid A
- Surfactant protein D
- Chitinase 1
- Krebs von den Lungen-6
- Cartilage oligomeric matrix protein

### ILD progression



#### Epidemiology

- Male sex
- Active smoker
- Older age at presentation

#### **Clinical features**

- Digital ulcers
- Arthritis
- · Increased oesophageal diameter
- · Pulmonary hypertension
- · Progressive skin fibrosis
- Renal disease
- Myocardial fibrosis

#### Physiology and imaging

- · Forced vital capacity (FVC) decrease of more than 10%
- More than 20% fibrosis on high-resolution CT
- · Pulmonary artery-to-aorta ratio of more than 1:1
- FVC decrease of 5–9% with decrease in diffusing capacity for carbon monoxide of more than 15%
- Usual interstitial pneumonia pattern

#### **Novel Biomarkers**

- Fractional excretion of nitric oxide
- Interleukin 10
- Carbohydrate antigen 15.3
- C-reactive protein
- Monocyte chemoattractant protein 1



### PFTs are a poor screening tool for ILD in patients with SSc

Retrospective study of 212 patients All had received CT imaging and PFTs in the **P**rospective **R**egistry of **E**arly **S**ystemic **S**clerosis (**PRESS**; 11 sites) 54% had radiographic ILD

<b>PFT Parameters</b>	N	Sensitivity	Specificity	PPV	NPV	Positive LR	Negative LR	FPR	FNR
FVC < 80%	212	63%	68%	70%	61%	2.0	0.5	0.32	0.37
TLC < 80%	146	46%	77%	74%	51%	2.0	0.7	0.23	0.54
DLCO < 80%	200	80%	51%	66%	68%	1.6	0.4	0.49	0.20
FVC or DLCO < 80%	199	85%	42%	64%	70%	1.5	0.4	0.58	0.15
FVC or TLC or DLCO < 80%	143	85%	42%	68%	66%	1.5	0.4	0.58	0.15

Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease



### **ILD patterns in SSc-ILD**

Characteristic	Nintedanib (n=288)	Placebo (n=288)	
Female – no. (%)	221 (76.7)	212 (73.6)	
Age – yr	54.6±11.8	53.4±12.6	
Body mass index – kg/m <sup>2</sup>	25.9±4.8	25.8±5.1	
Race – no. (%)†			
White	201 (69.8)	186 (64.6)	
Asian	62 (21.5)	81 (28.1)	
Black/African-American	20 (6.9)	16 (5.6)	
American Indian/Alaska Native/Native Hawaiian/other Pacific Islander	3 (1.0)	3 (1.0)	
Diffuse cutaneous SSc – no. (%)	153 (53.1)	146 (50.7)	
Years since onset of first non-Raynaud symptom – median (minimum, maximum)	3.4 (0.3, 7.1)	3.5 (0.4, 7.2)	
Extent of fibrosis on HRCT – %	36.8±21.8	35.2±20.7	
Honeycombing on HRCT – no. (%)	44 (15.3)	45 (15.6)	
Reticulation on HRCT – no. (%)	266 (92.4)	272 (94.4)	
Ground glass opacities on HRCT – no. (%)	241 (83.7)	246 (85.4)	
FVC			
ml	2459±736	2541±816	
% of predicted value	72.4±16.8	72.7±16.6	
DL <sub>co</sub> – % of predicted value <sup>‡</sup>	52.9±15.1	53.2±15.1	
Anti-topoisomerase antibody positive§ – no. (%)	173 (60.1)	177 (61.5)	

Retrospective study of 27 SSc-ILD patients undergoing Bx 51.9% NSIP pattern 29.6% UIP pattern 18.5% miscellaneous non-ILD pattern

All patients had limited skin involvement UIP pattern had a trend towards worse survival



## **Pulmonary Hypertension in SSc patients**

Estimated prevalence ranges from 8-15%

WHO group 1 (PAH)—most commonWHO group 2 (Due to left heart disease)WHO group 3 (Lung disease or hypoxia)

Increases morbidity and mortality

- Annual screening with a TTE
- Low threshold to repeat TTE or refer for RHC Dyspnea out of proportion to CT changes DLCO disproportionately low/declining Concerning exam findings (edema, RV heave)



### **Summary**

• ILD is a common complication of SSc

• ILD is associated with significant morbidity and mortality

- Rheumatologists and pulmonologists need to have an index of suspicion for the presence of ILD and SSc in their respective patient populations
- SSc patients should be carefully screened for the presence of PH

